跳至主要内容
临床试验/NCT03220425
NCT03220425已完成3 期

A Six Month, Multi-centre, Open-label, Parallel Efficacy and Safety Comparison of Insulin Detemir and NPH Insulin in Subjects With Type 1 Diabetes on a Basal-bolus Regimen.

Novo Nordisk A/S1 个研究点 分布在 1 个国家目标入组 752 人开始时间: 2001年2月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
752
试验地点
1
主要终点
The change in the level of glycosylated haemoglobin(HbA1c)

研究概览

简要总结

The aim of this trial is to evaluate the efficacy and safety of insulin detemir using the 2400 nmol/mL formulation to optimise dosing in subjects with type 1 diabetes on a basal (once daily)-bolus regimen.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed and dated informed consent obtained before any trial-related activities
  • Type 1 diabetes diagnosed and classified according to aetiology
  • Duration of type 1 diabetes equal to or more than 12 months
  • Glycosylated haemoglobin less than or equal to 12 percent based on analysis from central laboratory
  • Able and willing to perform self-blood glucose monitoring

排除标准

  • Proliferative retinopathy
  • Total basal insulin dose of more than 100 IU per day
  • Recurrent major hypoglycaemia - that would interfere with trial participation (as judged by the investigator)
  • Known unawareness of hypoglycaemia
  • Previous treatment with insulin detemir

研究组 & 干预措施

NPH insulin

Active Comparator

干预措施: NPH insulin (Drug)

Insulin detemir

Experimental

干预措施: Insulin detemir (Drug)

结局指标

主要结局

The change in the level of glycosylated haemoglobin(HbA1c)

时间窗: From start of treatment visit 2 (week 0) until end of treatment visit 8 (week 26)

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验